BHARAT BIOTECHS COVAXIN
COVID-19 Vaccination in India: Centre Creating ‘Artificial Scarcity’ of Coronavirus Vaccines To Benefit Bharat Biotech, Serum Institute', Says AAP Spokesperson Atishi
Bharat Biotech Likely to Commence Trials of Covaxin, Its COVID-19 Vaccine, on Children from Next Month
COVAXIN Phase 2 and 3 Trials for 2 to 18 Age Group Approved by DCGI, Bharat Biotech To Conduct Trials on 525 Healthy Volunteers
Google Trends